Analyst Jim Cramer identified The Clorox Company (CLX) as a potential investment opportunity despite recent underperformance. Clorox posted strong Q2 2025 results and raised its full-year outlook, pleasing investors and prompting suggestions for it as a strong dividend stock. Its success was reflected in its Q2 Earnings, which considerably exceeded estimates recording an EPS of $1.54 and revenue of $1.69 billion. Nonetheless, cautious outlook overshadowed Q2 beat, and shares saw some pressure. It also completed the divestiture of its Better Health VMS Business as part of its strategy.
Jim Cramer frequently commented on the company's performance, indicating a decline on profit lines due to weak earnings entirely. Nevertheless, the firm managed to beat estimates with significant results in gross margin expansion. Clorox also established a partnership with M2030 to advance supply chain climate action and announced the election of new board members. The company continues with its commitment to sustainability and safety. However, Clorox’s stock has seen volatilization with sharp rises and falls post-Q2 results, and is considered currently overpriced compared to other consumer staples stocks.
Clorox Company CLX News Analytics from Thu, 21 Mar 2024 07:00:00 GMT to Sat, 01 Mar 2025 18:15:31 GMT - Rating 5 - Innovation 2 - Information 8 - Rumor -4
